

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 356 826 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
29.10.2003 Bulletin 2003/44

(51) Int Cl.7: **A61K 47/48**, A61K 49/00,
A61K 39/35, A61K 39/36,
A61P 37/08

(21) Application number: **02008283.0**

(22) Date of filing: **22.04.2002**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: **BIOMAY Produktions- und Handels-
Aktiengesellschaft**
1030 Wien (AT)

(72) Inventors:
• **Grönlund, Hans**
181 61 Lidingö (SE)
• **Rönnelid, Johan**
756 45 Uppsala (SE)
• **Karlsson-Parra, Alex**
431 38 Mölndal (SE)

- **Hage-Hamsten, Marianne Van**
167 56 Bromma (SE)
- **Valenta, Rudolf**
2604 Theresienfeld (AT)
- **Vrtala, Susanne**
1210 Wien (AT)
- **Wiedermann, Ursula**
1130 Wien (AT)
- **Kraft, Dietrich**
1170 Wien (AT)

(74) Representative: **Keller, Günter, Dr.**
Lederer & Keller
Patentanwälte
Prinzregentenstrasse 16
80538 München (DE)

(54) **Microparticles comprising carbohydrate beads covalently linked with allergen**

(57) Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.

EP 1 356 826 A1

Description

[0001] The present invention relates to the field of immunotherapy and in particular to the treatment of patients suffering from allergic reactions against allergens, in particular allergens derived from plant pollen.

[0002] Allergen-specific immunotherapy which is mostly conducted by injecting allergen extracts into allergic patients was introduced many years ago. The occurrence of severe anaphylactic side effects caused by the injection of aqueous allergen extracts and the necessity to administer a great number of injections over long periods prompted the development of safe and efficacious allergen formulations. More than 60 years ago aluminium hydroxide-adsorbed allergen extracts were introduced for depot vaccination, showing improved immune stimulatory as well as reduced anaphylactic properties. Even today, aluminium hydroxide is by far the most common adjuvant used for injection immunotherapy.

[0003] Allergen-specific immunotherapy is one of the few known causative treatments of IgE-mediated allergy and numerous clinical studies document its clinical efficacy. Common clinical practise includes the subcutaneous injection of allergen extracts adsorbed to aluminium hydroxide with gradually increasing doses to a maintenance level and treatment periods up to 5 years or more. Aluminium hydroxide is preferred to other adjuvants (e.g., oil emulsions, liposome formulations) for injection immunotherapy of humans because it induces comparable little tissue reactions. Nevertheless aluminium hydroxide can cause local granuloma formation at the injection sites. Other major disadvantages of aluminium hydroxide are the unpredictable efficacy of adsorption of certain allergens/allergen extracts, the unpredictable stability of the adsorbents, the possibility that allergens are altered in the course of the adsorption process and the difficulties in assessing quality and quantity of allergens once that they are adsorbed to aluminium hydroxide.

[0004] It is an object of the present invention to provide improved forms of antigens which can be used in particular for the treatment of patients suffering from allergic reactions.

[0005] The present invention discloses
Microparticles comprising

- a) a bead essentially consisting of a carbohydrate and
- b) an allergen which is covalently bound to the bead.

The carbohydrate bead consists essentially of a threedimensionally linked Polymer which may be a polyarylamide, a vinyl polymer, a dextran or preferably agarose. Mixtures of the polymers can also be used. The carbohydrate-based particle consists of suitable polymer carbohydrates, preferably agarose which is linked in three dimensions. Suitable beads are commercially available, for example under the trademark Sepharose. The beads are small particles consisting of a gel-like carbohydrate which forms the support for the antigen. The microparticle consists of a carbohydrate-based bead which is covalently linked with an antigen at high density without dramatic alteration of its immunological properties.

[0006] The microparticles according to the present invention have a certain particle size which ranges from 0.1 μm to 10 μm and preferably from 0.5 μm to 5 μm . The size of the microparticles is essential. The size distribution means that the largest percentage, usually at least 80% of all beads are within the given range. Of course there are some beads outside this range since the diameter is distributed statistically. By applying special technique it is, however, possible to make sure that more than 99% of the beads are within the given range.

[0007] The microparticles of the present invention contain at least one antigen which is covalently linked to the carbohydrate bead. The antigen is a compound against which the immune-system of the animal or the human being to be immunized forms antibodies. The antigen may be any structure which forms an epitope. The antigen may be a polypeptide, a carbohydrate like for example glycosyl residues attached to a polypeptide or nucleic acids. In a preferred embodiment the antigen is an allergen which is derived from plant pollen. The surface structures of the plant pollen are the causative agents of allergic reactions. In preferred embodiments of the present invention the allergens are structures derived from grass pollen. In an especially preferred embodiment of the present invention the allergen is derived from timothy grass pollen.

[0008] The coupling of the carbohydrate-based beads to the antigen is based on the principle of forming a covalent bond between the carbohydrate backbone of the bead and a reactive group of the antigen. The covalent bond may be formed for example by a cyano bromide activation resulting in stable formation of amid bonds which can be applied for most proteins and peptides with high efficacy. Alternative binding methods which are well known in the art can be also used depending on the antigen to be bound to the bead.

[0009] In the experiments of the present application the antigen to be tested was purified recombinant Phlp 5b, a major timothy grass pollen allergen which was coupled to carbohydrate-based particles (CBP). In the examples the same antigen was only mixed with CBP (as comparative test) and in another comparative test the antigen was absorbed to aluminium hydroxide.

[0010] In the examples the Phlp 5b formulations were used to immunize mice and the levels, kinetics and profiles of antibody responses were analyzed.

[0011] In another set of experiments cytokine production in mouse spleen-cell-cultures was investigated and the injection sites were further analyzed by histopathology. The CBP-rPhl p 5b induced mouse antibodies were also tested for cross-reactivity to natural group 5 allergens from various grasses and their ability to inhibit the IgE-binding of grass pollen allergic patients to the allergen was studied.

[0012] It has been found that the microparticles of the present invention elicited comparable immune responses but less granulomatous tissue reactions than aluminium hydroxide. Therefore the microparticles do have less side-effects. Furthermore the antibodies induced by the microparticles of the present invention blocked allergic patients IgE-binding to rPhl p 5b which shows that the microparticles can be used successfully for the treatment of allergic patients.

[0013] The present invention discloses also a medicament for the treatment of the immune system which comprises microparticles according to the present invention. Such a medicament can be administered nasally, rectally or preferably parenterally. The microparticles can be included in suitable pharmaceutical formulations like solutions for injection, rectal foams or nasal sprays. It is also possible to prepare suitable ointments or plasters. The present invention provides also a diagnostic test system for the measurement of released cell mediators which comprises microparticles according to the present invention. One system is described in detail in example 2 and method 6.

[0014] The results of the present experiments show that the microparticles may represent a useful support and adjuvant for allergen-specific immunotherapy yielding comparable immune responses as aluminium hydroxide. The experiments show that purified rPhl p 5b allergen which is covalently bound to the carbohydrate-based bead induced strong IgG1, IgG2a/b and IgG3 antibody responses in mice. Those antibodies cross-reacted with natural group 5 allergens from all 5 grass species containing group 5 allergens and perhaps more important competed with the binding of grass pollen allergic patients IgE-antibodies to Phl p 5b. This finding suggests that the antibodies induced by the microparticles have the desirable features of blocking antibodies. Such blocking antibodies which are induced in the course of immunotherapy have beneficial effects as they can inhibit the allergen induced effect of cell activation and the IgE mediated presentation of allergens to T-cells.

[0015] The microparticles of the present invention offer several advantages compared to alternatively usable forms of immunotherapy like, for example, the use of aluminium hydroxide.

[0016] Since the coupling of the antigen to the beads uses well described and reproducible procedures, it is exactly predictable which amount of antigen is loaded on the beads. Therefore the beads are covered with the antigen in high density, with a high yield and in a reproducible amount.

[0017] Another advantage can be seen in the fact that the antigens which are covalently conjugated to the beads are presented in a very efficient way by antigen presenting cells to the involved cells of the immunosystem. It can be concluded from the experiments which show that the cytokine response is much more vigorous in the group treated with microparticles of the present invention compared to the control group wherein the antigen was absorbed to aluminium that the cellular immune response is stimulated.

[0018] Another advantage is that the carbohydrate-based beads, in particular sepharose are highly biocompatible. Therefore the vaccination formulations can be administered via different routes whereby the parenteral route is preferred. It is, however, also possible to administer the medicaments of the present invention by the oral, nasal, rectal or intra-venous administration. The subcutaneous or intra-muscular application is, however, preferred.

[0019] The following experiments show that the present microparticles are well tolerated when exposed to a variety of cell types in tissue culture and as column matrix in clinical ex-vivo treatments. This is in particular supported by the experiments which show that the immunisation of mice with the microparticles of the present invention induced less granulomatous reactions than the use of aluminium hydroxide under comparable treatment.

I) METHODS

1) Patient sera

[0020] Nine patients with a documented clinical history of allergy to timothy grass pollen, sensitised to rPhl p 5b and a timothy grass pollen RAST class value of 2 or higher were included in the study together with control sera.

2) Recombinant allergen

[0021] cDNA coding for the major allergen rPhl p 5b was obtained by PCR according to the published rPhl p 5b sequence [Bufe et al. "Major allergen Phl p 5b in timothy grass is novel pollen Rnase". FEBS Lett 1995;363:6-12.]. The Phl p 5b cDNA was subcloned into pET 17b (Novagen, Madison, WI) expressed, in *E coli* BL-21 (DE3) and purified to homogeneity as described [Vrtala et al. "Immunologic characterization of purified recombinant timothy grass pollen (*Phleum pratense*) allergens (Phl p 1, Phl p 2, Phl p 5)". J Allergy Clin Immunol 1996;97:781-7.].

3) Preparation of conjugates and adsorbates

[0022] Cyanogen bromide-activated spherical Sepharose particles (CBP), i.e. beaded agarose, with a mean diameter of 2.1 micrometer were provided by Pharmacia Diagnostics, Uppsala, Sweden. The beads were cyanogen bromide activated as described in the prior art [Axén et al. "Chemical coupling of peptides and proteins to polysaccharides by means of cyano halides". *Nature* 1967;214:1302-1304.]. Prior to conjugation 4 mg of lyophilized rPhl p 5b was dissolved in 8 ml 0.1 M carbonate-buffer pH 8.0 and added to 110 mg of activated particles in 2.0 ml 0.1 M carbonate-buffer pH 8.0. The allergen was conjugated to the particles by end-over-end mixing for 1 h at room temperature. CBP-rPhl p 5b were centrifuged at 1000 x g for 5 min. Coupling efficiency was estimated to be >95% by measuring protein concentration by UV absorbance at 280 nm in supernatants before and after conjugation. Remaining active groups were blocked by resuspending the particles in 5 volumes of 0.1 M glycine pH 8.5 and incubated by end-over-end mixing for 1 hour. The gel was further washed by alternatively with 0.1 M sodium acetate, 1.0 M NaCl pH 4.0 and 0.1 M Tris, 1.0 M NaCl pH 8.0, 5 volumes each. Finally the CBP-rPhl p 5b was transferred to 50mM phosphate buffer, 0.15 M NaCl, 10mM EDTA 0.02% NaN₃, 0.05% Tween 20 pH 7.5 and stored at +4°C until use. Stability of the covalent link between rPhl p 5b and CBP was confirmed after three months of storage at +4°C by analysis of rPhl p5b in the supernatant. Aluminium hydroxide (Alum) adsorbates were prepared for comparative examples freshly prior to injection as described [Vrtala et al. "T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies". *J Immunol* 2000;165:6653-9.]. Briefly, aluminium hydroxide, AluGel-S (Serva, Heidelberg; Germany) was diluted 1:1 in PBS and mixed with rPhl p 5b to yield 5 µg per 100 µl gel.

4) Immunisation of mice

[0023] Three groups, each consisting of five female 6-8 weeks old BALB/c mice (Charles River, Kislegg, Germany) were immunised with covalently bound CBP-rPhl p 5b (Group I), rPhl p 5b-Alum (Group II) as control and as a second control, rPhl p5b was mixed with CBP (group III). The groups, treatment and time of immunisation are given in the following table I:

TABLE I.

Groups of immunized mice			
Group	Treatment	Days of immunization	Day of sacrifice
Group I	CBP-rPhl p 5b	0, 28, 63, 121	128
Group II	Alum-rPhl p 5b	0, 28, 63, 121	128
Group III	CBP+rPhl p 5b	0, 28, 63, 121	128

[0024] The mice were immunised subcutaneously in the neck with 5 µg of rPhl p 5b in 100 µl of suspensions, from each of the three preparations. Immunisations were given and blood was taken on days 0, 28 and 63. On day 121 a booster injection was given and 7 days later the animals were sacrificed and spleen cells were prepared for cytokine measurements. The animals were kept in the animal care unit of the Department of Pathophysiology of the University of Vienna according to the local guidelines for animal care.

5) ELISA detection of allergen-specific antibodies

[0025] All 15 mice were bleed and antibodies IgG1, 2a/b, 3 and IgE specific to rPhl p 5b were analyzed individually in ELISA as described by [Vrtala et al. "Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE, inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation". *J Immunol* 1998;160:6137-40.]. Ninety-six well micro titre plates (Nunc, Roskilde, Denmark) were coated with 100 µl, 5 µg /ml rPhl p 5b in PBS over night at +4°C. The plates were washed 2 times with 0.05% Tween 20 in PBS (WB). To reduce unspecific binding, 200 µl WB-1% BSA was added for 2.5 h at room temperature. One hundred µl mouse serum diluted in WB-0.5% BSA, 1:1000 for IgG1, 1:100 for IgG2a/b and 3 and 1:20 for IgE respectively, was added per well and incubated over night at +4°C, followed by washing 5 x 250 µl with WB. One hundred µl rat anti-mouse IgG1, 2a/b, 3 and IgE (PharMingen, San Diego, CA) respectively, diluted 1:1000 in WB-0.5% BSA were incubated over night at +4°C followed by washing. One hundred µl horseradish peroxidase labeled sheep anti-rat IgG diluted 1:1000 in WB-0.5% BSA, was incubated 2h in room temperature followed by washing 5 x 250 µl with WB ABTS (Sigma St Louis) was used as substrate and the colour reaction was read at 405 nm with a Dynatech microplate reader (Denkendorf, Germany).

[0026] Group 5 allergens in different grass pollen were detected by ELISA. Pollen allergen extracts in PBS from

Phleum pratense, *Lolium perenne*, *Poa pratensis*, *Anthoxanthum odoratum*, *Triticum sativum*, *Avena sativa*, *Cynodon dactylon*, *Zea mays* and *Pharagmites antralis* (Allergon AB, Vålänge, Sweden) were coated to 96-well ELISA plates (Nunc). After blocking and washing, plate-bound extract were exposed to a mouse serum pool from group I diluted 1:100 in PBS, 0.5% BSA and 0.05% Tween 20. For control purposes, a corresponding pre-immune serum pool was used. Bound IgG antibodies were detected with horseradish peroxidase-labeled sheep anti-mouse IgG antiserum (Amersham, Buckinghamshire, UK) diluted 1:1000 in 0.05% Tween 20-PBS.

6) Measurement of cytokine production in spleen cell cultures

[0027] For determination of IL-4, IL-5 and IFN- γ production, spleen cell suspensions from immunized mice were cultured in 48-well plates (Costar, Cambridge, MA) with and without timothy grass pollen extract (25 μ g/well) at a concentration of 5×10^6 /well. Supernatants were taken 24 hours for IL-4 and IL-5 and 48 hours for IFN- γ after antigen stimulation and stored at -20°C until analysis. Levels of IL-4 and IL-5 were measured by ELISA (Endogen, Cambridge; Mass). The sensitivity of the tests were < 5 pg/ml. IFN- γ levels were measured in 96-well plates (Nunc, Maxisorp) coated with rat anti-mouse IFN- γ (Endogen, Woburn, MA) at a concentration of 0.5 μ g/ml carbonate buffer pH 9.6 for 6 hours at room temperature. Thereafter biotin labeled rat anti-mouse IFN- γ antibodies (Endogen) were applied at a concentration of 0.1 μ g/ml, followed by peroxidase-conjugated streptavidin (1:10 000 in PBS/4% BSA; Endogen) for 30 min. For colour development TBM substrate (Chemicon, Temecula, CA) was used and the absorbance was measured at 450 nm. The sensitivity of the assay was < 15 pg/ml. Results reflect the measured cytokine levels in pg/ml after subtraction of baseline levels of non-stimulated cultures.

7) Histopathological analysis of skin sections

[0028] Skin was excised from the injection areas (1.5 cm²), cut into 4 mm thick strips, fixed with 7.5% formalin, pH 7.5, and embedded in paraffin. Five μ m sections were stained with hematoxylineosin or Giemsa.

8) ELISA competition assay

[0029] ELISA plates were coupled with rPhl p 5b (0.1 μ g/well), blocked and washed as described for the ELISA assay above. Plates were exposed first to pooled sera of mice immunized either with CBP-rPhl p 5b (group I) or Alum-rPhl p 5b (group II) or, for control purposes, with the corresponding pre-immune serum pools diluted 1:100 over night at 4°C. After washing, the plates were incubated with sera from grass pollen allergic patients diluted 1:5. Bound human antibodies were detected with an alkaline-phosphatase conjugated mouse monoclonal antibody (PharMingen). The inhibition of allergic patients' IgE binding to rPhl p 5b by the mouse immune sera was calculated using the formula $100 - (\text{OD second bleeding} / \text{OD pre-immune serum}) \times 100$.

9) Statistical analysis

[0030] The non-parametric test Kruskal-Wallis ANOVA was used for evaluation of allergen specific antibody responses and group 5 allergen cross-reactivity between grass-species. Mann-Whitney U test was used for evaluation of mouse serum blocking of human IgE binding. $P < 0.05$ was considered statistically significant.

EXAMPLE 1

CBP-bound rPhl p 5b induces strong allergen-specific antibody responses

[0031] In order to compare levels and kinetics of rPhl p 5-specific antibody responses sera from all groups of mice and bleedings were analyzed separately for IgE and each IgG subclass on one ELISA plate. All three groups showed an increase of rPhl p 5b-specific antibody responses in the course of the immunizations, which peaked after the second immunization. The results of example 1 are shown in Figure 1. **FIGURE 1** shows IgE and IgG subclass responses of mice to ELISA plate-bound rPhl p 5b. The optical density values (OD 405 nm) displayed on the y-axis correspond to the levels of Phl p 5b-specific IgE, IgG₁, IgG₂, and IgG₃ antibodies in the sera of the three mouse groups (Group I: CBP-rPhl p 5; Group II: Alum-rPhl p 5; Group III: CBP+rPhl p 5). In Group III r Phl b5b was only mixed with CBP. Results are displayed for preimmune sera (P), the first (1) and second (2) bleeding as box plots where 50% of the values are within the boxes and non-outliers between the bars. Filled squares denote median values, open circles outliers and stars extremes of each group, respectively.

[0032] Mice having received co-administered rPhl p 5b and CBP without covalent coupling (group III) showed significantly lower antibody levels after the first immunization than mice receiving CBP- or Alum-bound allergen. Both,

the levels and patterns, of rPhl p 5b-specific antibody responses were similar in mice treated with CBP-rPhl p 5b, (group I) and Alum-rPhl p 5b, (group II) showing specific IgE antibody production but also specific IgG₂ and IgG₃-responses. The kinetics and magnitudes of rPhl p 5b-specific IgG₁ responses were similar in groups I and II.

Example 2

Mice immunized with CBP-bound rPhl p 5b show strong cytokine responses to timothy grass pollen extract

[0033] The profile of IFN- γ , IL-5 and IL-4 secreted by spleen cells from mice of the three immunization groups cultivated in the presence of natural timothy grass pollen extract was similar in all three groups. **FIGURE 2** shows *In vitro* cytokine production in spleen cell cultures. IFN- γ , IL-5 and IL-4 levels were measured in supernatants of antigen stimulated spleen cells of mice which were immunized with CBP-rPhl p 5b - group I (black bars), Alum-rPhl p 5b -group II (white bars) or with CBP + rPhl p 5 -group III (hatched bars). The bars indicate the mean of 5 individual values, the error bars the standard error of the mean. Mann Whitney U-Test, * $p < 0.05$; *** $p < 0.001$.

[0034] From the data it can be concluded that spleen cells from mice which had received CBP-conjugated rPhl p 5b mounted significantly stronger cytokine production (IFN- γ , IL-5) than spleen cells from mice treated with Alum-adsorbed rPhl p 5b. The lowest release of cytokines was found in spleen cells cultures from mice which had received a co-administration of rPhl p 5b and CBP.

Example 3

CBP-bound rPhl p 5b induces less granulomatous tissue reaction than Alum-adsorbed allergen

[0035] In order to analyse the tissue-reactions at the injection sites, skin sections were taken from the mice of group I and group II and processed for histological examination. Representative skin sections of CBP-rPhl p 5b and Alum-rPhl p 5b immunized mice were further examined. Injection sites from CBP-rPhl p 5b and Alum-rPhl p 5b immunized mice were histopathologically analyzed.

[0036] In mice receiving Alum, an overall more pronounced inflammatory reaction and additional granulomatous responses could be seen with predominantly foam cells at the outer rim and granular debris in the center of the granuloma. The inflammatory tissue reactions of CBP-rPhl p 5b immunized mice tended to be smaller and contained less granular debris than those of the Alum-treated mice. Close ups of tissue sections of mice immunized with CBP- and Alum-bound rPhl p 5b were further analyzed. They contained a mixed cellular inflammatory infiltrate, including macrophages and lymphocytes with occasional mast cells and eosinophils at injection sites in the deep dermis, in part with granulomatous changes.

Example 4

Mice immunized with CBP-bound rPhl p 5b exhibit IgG cross-reactivity with natural pollen extracts from grasses containing group 5 allergens

[0037] To study whether immunization with CBP induces IgG antibodies which cross-react with group 5 allergens from pollen of other grass species, ELISA experiments were performed with a pre-immune serum pool and a serum pool containing sera from the second bleeding. The results are shown in Figure 3. **FIGURE 3** demonstrates cross-reactivity of IgG antibodies from CBP-rPhl p 5-immunized mice with natural group 5 allergens from 9 grass species. Optical density values (OD 405 nm) corresponding to the serum IgG antibody levels to pollen extracts from 9 grass species (y-axis). *Phleum pratense*, *Lolium perenne*, *Poa pratense*, *Anthoxanthum odoratum*, *Triticum sativum*, *Avena sativa*, *Cynodon dactylon*, *Zea mays*, *Phragmites australis* are displayed for a serum pool collected before (P) the immunizations and during the second bleeding (2) at the x-axis.

[0038] rPhl p 5b -specific IgG antibodies reacted with natural group 5 allergens from timothy grass (*Phleum pratense*) and from five grass species (*Lolium perenne*, *Poa pratense*, *Anthoxanthum odoratum*, *Triticum sativum*, *Avena sativa*). The highest levels were recorded to *Poa pratense*. No IgG reactivity to pollen extracts from grasses (*Cynodon dactylon*, *Zea mays*, *Phragmites australis*) lacking group 5-related allergens was found. The pre-immune serum pool showed no significant IgG reactivity to any of the nine grass pollen extracts.

Example 5**Sera from mice immunized with CBP-bound rPhl p 5b inhibit the binding of allergic patients' IgE to the allergen**

[0039] Whether sera from mice immunized with CBP-rPhl p 5b or Alum-rPhl p 5b can inhibit the binding of grass pollen allergic patients' IgE to rPhl p 5b was studied by ELISA competition experiments. Microtitre-bound rPhl p 5b was pre-incubated with a serum pool taken on day 63 obtained from mice immunized with CBP-rPhl p 5b or Alum-rPhl p 5b and, for control purpose, with a corresponding pool of pre-immune sera and then exposed to serum IgE from nine grass pollen allergic patients.

The results are shown in Figure 4. **Figure 4** shows the inhibition of grass pollen allergic patients' IgE binding to rPhl p 5b by murine sera. ELISA plate-bound rPhl p 5b was preincubated with a serum pool from CBP-rPhl p 5b- (Group I) or from Alum-rPhl p 5b- (Group II) immunized mice. The percentage inhibition of IgE binding determined for sera from nine grass pollen allergic patients is displayed on the y-axis. Boxes and horizontal bars denote 50% of the values and non-outlier range, respectively. Mean values are indicated and open circles denote outliers. Sera from group I mice immunized with CBP-rPhl p 5b, inhibited allergic patients (n=9) IgE binding to rPhl p 5b from 37 to 80% (mean 59.%) whereas an inhibition between 51 to 90% (mean 67.9%) was observed with sera from group II (Alum-rPhl p 5b). Although the inhibition of IgE binding obtained with the sera from mice treated with Alum-bound-rPhl p 5b was somewhat higher than that obtained with sera from mice of group I, no significant difference between group I and group II in terms of blocking capacity was observed ($p=0.31$, Mann-Whitney U test).

Claims**1. Microparticle comprising**

- a) a bead essentially consisting of a cross-linked carbohydrate and
- b) an antigen which is covalently bound to the bead.

2. Microparticle according to claim 1 wherein the carbohydrate bead consists essentially of agarose.**3. Microparticle according to claim 1 or 2 wherein the antigen is an allergen.****4. Microparticle according to claim 3 wherein the allergen is derived from plant pollen.****5. Microparticle according to claim 4 wherein the allergen is derived from grass pollen.****6. Microparticle according to claim 5 wherein the allergen is derived from timothy grass pollen.****7. Microparticle according to any one of claims 1-6 wherein the particle size ranges from 0.1 μm to 10 μm .****8. Microparticle according to any of claims 1-7 wherein the particle size ranges from 0.5 μm to 5 μm .****9. Microparticle according to any of claims 1-8 characterized in that the microparticle is used for vaccination.****10. Microparticle according to any of claims 1-8 characterized in that the microparticle is used for the treatment of allergy.****11. Medicament for the treatment of the immune system characterized in that it comprises microparticles according to any of claims 1 - 10.****12. Medicament according to claim 11 characterized in that it is prepared for parenteral application.****13. Diagnostic test system for the measurement of released cell mediators characterized in that it comprises microparticles according to any of claims 1-8.****14. Diagnostic test system according to claim 13 wherein the released cell mediator to be measured is an interleukin.**

Fig. 1




Fig.2




Fig.3





Fig 4.





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 8283

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 5 849 884 A (BROWN LARRY R ET AL) 15 December 1998 (1998-12-15) * column 14, line 15 - line 19; claims 1,4,7 * * column 15, line 44 - line 47 * ---	1-14	A61K47/48 A61K49/00 A61K39/35 A61K39/36 A61P37/08
Y	WO 95 19437 A (MOHAPATRA SHYAM S ;UNIV MANITOBA (CA); SEHON ALEC H (CA)) 20 July 1995 (1995-07-20) * claims 1,3,7,17,21,36,37; example 2 * ---	1-14	
X		1	
Y	EP 0 451 800 A (ABBOTT LAB) 16 October 1991 (1991-10-16) * claims 1,2,4 * ---	1-14	
Y	GEETA N SAI ET AL: "In vitro immunization of murine lymphocytes using immobilized immunogens." BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 24, no. 1, 1996, pages 61-64, XP008009290 ISSN: 0885-4513 * abstract * ---	1-14	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
Y	SCHRAMM G ET AL: "'Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 FEB 1999, vol. 162, no. 4, 15 February 1999 (1999-02-15), pages 2406-2414, XP002216586 ISSN: 0022-1767 * page 2413, column 2, paragraph 3 * --- -/--	1-14	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 16 October 2002	Examiner Berte, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03/82 (P4/01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 8283

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	WO 98 43657 A (MERCK PATENT GMBH ;MUELLER WOLF DIETER (DE); BUFE ALBRECHT (DE); F) 8 October 1998 (1998-10-08) * abstract; claims * -----	1-14	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 16 October 2002	Examiner Berte, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 00 8283

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

16-10-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5849884	A	15-12-1998	US 5484894 A	16-01-1996
			US 5981719 A	09-11-1999
			US 6268053 B1	31-07-2001
			US 6090925 A	18-07-2000
			US 5554730 A	10-09-1996
			AT 163230 T	15-02-1998
			AU 6358594 A	26-09-1994
			CA 2157793 A1	15-09-1994
			DE 69408527 D1	19-03-1998
			DE 69408527 T2	04-06-1998
			EP 0688429 A1	27-12-1995
			EP 0809110 A1	26-11-1997
			ES 2113094 T3	16-04-1998
			JP 8507806 T	20-08-1996
			WO 9420856 A1	15-09-1994
			US 5578709 A	26-11-1996
WO 9519437	A	20-07-1995	AU 1410995 A	01-08-1995
			CA 2181142 A1	20-07-1995
			WO 9519437 A1	20-07-1995
EP 0451800	A	16-10-1991	US 5091318 A	25-02-1992
			AU 634647 B2	25-02-1993
			AU 7433091 A	17-10-1991
			CA 2039958 A1	14-10-1991
			EP 0451800 A1	16-10-1991
			JP 4225163 A	14-08-1992
WO 9843657	A	08-10-1998	DE 19713001 A1	01-10-1998
			WO 9843657 A2	08-10-1998
			EP 1009419 A2	21-06-2000
			HU 0001552 A2	28-09-2000
			JP 2002511842 T	16-04-2002
			PL 335981 A1	05-06-2000

EPO FORM P/459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82